Rigel Pharma (RIGL) Tops Q2 EPS by 12c
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.67 --0%
Revenue Growth %: +15.2%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.2%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of $0.04, $0.12 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.89 million versus the consensus estimate of $25.7 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- Merck (MRK) PT Raised to $170 at Guggenheim
- Freedom Broker Upgrades Costco Wholesale (COST) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
